BC Innovations | Oct 26, 2017
Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
BC Extra | Oct 13, 2017
Politics & Policy

Court ruling could shield drugmakers from some RICO suits

An appeals court ruling could prevent drug and medical device companies from being sued under the Racketeer Influenced and Corrupt Organizations Act in certain cases. The U.S. Court of Appeals for the Seventh Circuit in...
BioCentury | Sep 19, 2016
Product Development

Getting ahead of headache

After several false starts, investments in CGRP inhibitors are bearing fruit in the clinic - if not exactly the prize pumpkins once hoped for from the class. Still, if the sponsors developing these products can convince...
BC Week In Review | May 13, 2013
Clinical News

Depakote divalproex regulatory update

FDA contraindicated valproate products, including all formulations of AbbVie's Depakote divalproex, to prevent migraines in pregnant women after data from the agency's Neurodevelopmental Effects of Antiepileptic Drugs study showed an increased risk of lower IQ...
BC Week In Review | May 14, 2012
Company News

Abbott neurology news

Abbott will pay $1.5 billion to federal and state authorities to resolve criminal and civil liability regarding past marketing activities for neurology drug Depakote divalproex. Under the settlement, Abbott pleaded guilty to a misdemeanor violation...
BC Extra | Oct 20, 2011
Financial News

Abbott beats Street

Abbott Laboratories (NYSE:ABT) reported 3Q11 non-GAAP diluted EPS of $1.18, beating by a penny the Street's estimate of $1.17 and up 12% from $1.05 in 3Q10. The results include a $1.5 billion charge for litigation...
BC Week In Review | Oct 10, 2011
Company News

Intas Pharmaceuticals, AstraZeneca, Handa Pharmaceuticals neurology, generics news

AstraZeneca settled a pair of suits filed in the U.S. District Court for the District of New Jersey regarding ANDAs for generic versions of antipsychotic drug Seroquel XR quetiapine. Under the settlements, AstraZeneca granted Handa...
BC Week In Review | Aug 1, 2011
Clinical News

Seroquel XR quetiapine regulatory update

FDA updated the label of atypical antipsychotic drug Seroquel XR quetiapine from AstraZeneca to warn about the risk of QT prolongation when given in combination with other drugs that are known to prolong QT. The...
BC Week In Review | Dec 14, 2009
Clinical News

Gabitril tiagabine: Post-marketing study data

Researchers at the University of Illinois at Chicago and colleagues reported data from a pharmacoepidemiologic study in 47,918 bipolar patients showing that there was no significant difference in suicide attempt rates in patients treated with...
BC Week In Review | Jun 29, 2009
Clinical News

Depakote ER divalproex regulatory update

After a post-marketing review of events from FDA's Adverse Events Reporting System (AERS), the agency identified 6 cases of developmental delay in the absence of teratogenicity associated with maternal use of Abbott's divalproex during pregnancy...
Items per page:
1 - 10 of 43